Introduction
============

Type 1 diabetes is an autoimmune disease, and the prominent population affected by the disease is teenagers. In recent years, the number of individuals diagnosed with the disease has increased. Once affected by the disease, the patient undergoes lifelong insulin treatment, which can pose an economic burden to the patient and family. Patients with type 1 diabetes suffer from multiple complications, which can lead to disabling and lethal factors ([@b1-etm-0-0-3694]).

To the best of our knowledge, few studies are available on the exact pathogenesis of type 1 diabetes, the variation of patient blood and the pancreatic tissue immune microenvironment ([@b2-etm-0-0-3694]--[@b4-etm-0-0-3694]). Non-obese diabetic (NOD) mice can spontaneously generate autoimmune disease, and their pathogenic process is similar to that of type 1 diabetes of human beings. Consequently, a NOD rodent animal model should be established to probe into morbidity and develop a treatment intervention mechanism for human type 1 diabetes ([@b5-etm-0-0-3694]). Exendin-4 is a type of polypeptide hormone separated from Gila monster saliva. This hormone is a broad application prospect in treating type 2 diabetes ([@b6-etm-0-0-3694],[@b7-etm-0-0-3694]). However, there is little research or studies on exendin-4 as an intervention mechanism in type 1 diabetes treatment. In order to determine the influence of exendin-4 intervention on NOD mouse blood and the pancreatic tissue immune microenvironment, a NOD mouse model was established for the experiments. A variation in T-cell subset CD8, CD4 and CD25 in NOD mouse peripheral blood and pancreatic tissue, as well as in the contents of cell factors IL-2, IFN-γ and IL-10 after low-dose, medium-dose and high-dose exendin-4 intervention was observed.

Materials and methods
=====================

### Materials

A total of 40 NOD/Lt mice were purchased from the Institute of Experimental Animals of the Chinese Academy of Medical Sciences. There were 20 male and 20 female mice, with a weight of 17--25 g. Exendin-4 reagent (Kangtai Biotechnology, Beijing, China); hematoxylin and eosin (H&E) dye liquor (Beijing Solarbio Science and Technology, Co., Ltd., Beijing, China); IL-2, IL-10 and IFN-γ reagent kits (Shanghai Biotechnology, Shanghai, China); monoclonal CD4 rabbit antibody (Abcam, Cambridge, MA, USA; catalog no.: ab133616; dilution, 1:100) and monoclonal CD8 rabbit antibody (Abcam; catalog no.: ab22378; dilution, 1:100); a flow cytometer (Beijing Kexue Yingye Science and Technology Development, Beijing, China); microplate reader (Jinan Guangyao Medical Equipment, Jinan, China); centrifugal machine (Shanghai Puyuan Instrument, Shanghai, China); and an optical microscope (Shenzhen Final Technology, Shenzhen, China) were used in the study.

The present study was approved by the ethics committee of Fujian Medical University (Fujian, China).

### Methods

A random number table was used to divide 40 clean and healthy NOD mice into 4 groups (n=10/group) as follows: One blank control group D with normal saline intervention, and the remaining three groups with exendin-4 intervention. According to the different exendin-4 doses of 2, 4 and 8 µg/kg/day, they were called the low-dose group A, medium-dose group B and high-dose group C, respectively. The four groups of mice were intervened for 8 weeks, after which they were sacrificed by cervical dislocation. An inner canthus method was used to take \~1 ml of whole blood, which was then centrifuged at 5,000 × g for 10 min at 4°C. Serum was kept at −20°C to test serum IL-2, IL-10 and IFN-γ. Pancreatic tissues were selected to conduct T-cell subset determination, while other subsets continued to be observed.

### Observation of pancreatitis infiltration degree

Pancreatic samples were embedded with paraffin, and then turned into tissue sections with H&E dyeing to be observed under a light microscope (Olympus, Tokyo, Japan). Pathology personnel used a double-blind method to determine the infiltration degree of pancreatitis. The grade of pancreatitis infiltration degree was divided as follows: i) Grade 0: Pancreas islet was complete without lymphocyte infiltration; ii) grade 1: lymphocytes infiltrated around the pancreas islet or \<25% pancreas islet area was affected; iii) grade 2: 25--50% pancreas islet area was affected; and iv) grade 3: \>50% pancreas islet area was affected. According to the above grading standard, the pancreatic sections of the four groups were observed under a ×5-x400 microscope.

### Assessment of local expression of pancreatic IL-10

Immunohistochemistry was used to observe the expression of the *IL-10* gene in local pancreatic samples. Brownish granules in cytoplasm were considered positive cells. Positive cell percentage and dyeing intensity were calculated. The positive cell percentage was calculated as: i) \<1% was 0; ii) 1--10% was 1; iii) 11--50% was 2; iv) 51--80% was 3; and v) \>80% was 4. The dyeing intensity of granules was calculated as: i) No dyeing was 0; ii) faint yellow was 1; iii) yellow was 2; and iv) brown was 3. The product of positive cell percentage and dyeing intensity determined the immunohistochemistry score as follows: 0 score (−); 1--4 scores (+); 5--8 scores (++); and 9--12 scores (+++).

### Determination of pancreatic tissue T-cell subset

After the mice were sacrificed, they were sterilized with alcohol. Pancreatic tissues were separated through an aseptic technique. Nearby connective tissues and pancreatic tissues were removed and rinsed twice in Hanks\' liquid. Ophthalmic scissors were used to cut the tissues into pasty sections. A tip sucker was used to blow and disperse pancreatic cells, while a 300-mesh net was used to implement infiltration. A lymphocyte-separating medium was used to extract lymphocytes at rotating speeds of 400 × g. They were then centrifuged for 20 min. The suspended layer of lymphocytes was extracted after a 2 ml pH 7.4 phosphate buffer saline (PBS) working solution was added. The lymphocytes were centrifuged for 5 min at 800 × g. The supernatant was discarded, and the cell concentration was adjusted to 2×10^9^ cells/l. Under a microscope, 0.4% trypan blue was used to count living cells. The cell survival rate was determined to be \>95%. A 100 µl pancreatic single-cell suspension at a concentration of 2×10^9^/ml was measured at 25°C and kept in the dark. The suspension was then incubated with 10 µl CD8-FITC and 10 µl CD4-PE fluorescent antibody for 15 min. A 2-m erythrocyte lysate buffer was added to the suspension to incubate it for 10 min. A 2-ml PBS solution was then added to conduct centrifugation at 800 × g for 5 min. PBS washing was then repeated twice (the method used before), the supernatant was removed, and 200 µl PBS solution was added to each tube to conduct FCM detection. Macintosh (Apple, Inc., Cupertino, CA, USA) was the data processing system used. Cells were analyzed using CellQuest software (BD Biosciences, San Jose, CA, USA). Grating was conducted on lymphocytes on forward and lateral angular scattering diagrams. A logarithmic method was used to acquire fluorescence signals before 1×10^4^ cells were taken and analyzed under the same software. Serum of IL-2, IL-10 and IFN-γ were determined using ELISA. Operating steps were performed with ELISA reagent kits of IL-2, IL-10 and IFN-γ. The samples were determined in the same batch.

### Statistical analysis

SPSS 21.0 statistical software (IBM SPSS, Armonk, NY, USA) was used to conduct statistical analysis. Experimental data were presented as mean ± standard deviation, t-test or t\'-test. A χ^2^ test was conducted on experimental results. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Pancreatitis infiltration degree

Pancreatitis of mice in control group D was mainly at grade 2 and 3. Under a light microscope, it was observed that pancreatic cell morphology was in disorder, and the size and quantity of the pancreas was small. Mouse pancreatitis in exendin-4 low-dose group A, medium-dose group B and high-dose group C was mainly at grade 0 and 1. Under the light microscope, it was observed that pancreatic cell morphology improved, infiltration degree of lymphocyte improved and pancreatic islet size was restored somewhat.

### Local expression of IL-10 in pancreatic tissues

Under the light microscope, numerous brown granules with deep color within pancreatic sample cells in exendin-4 low-dose group A, medium-dose group B and high-dose group C ([Figs. 1](#f1-etm-0-0-3694){ref-type="fig"}--[3](#f3-etm-0-0-3694){ref-type="fig"}) were observed. There were a few brown granules within pancreatic sample cells in control group D ([Fig. 4](#f4-etm-0-0-3694){ref-type="fig"}). IL-10 immunohistochemistry scores in low-dose group A, medium-dose group B and high-dose group C were 3.82±0.72, 4.34±0.86 and 4.81±0.94, respectively, all of which were higher than the immunohistochemistry score of 2.25±0.63 in group D.

### Test results of FCM

The CD4+CD25+T-cell proportions in pancreatic tissues in exendin-4 low-dose group A, medium-dose group B and high-dose group C were 5.31, 5.53 and 5.74%, respectively, all of which were higher than the CD4+CD25+T-cell proportions of 1.62% in group D, as shown in [Figs. 5](#f5-etm-0-0-3694){ref-type="fig"}--[8](#f8-etm-0-0-3694){ref-type="fig"} (right upper quadrant of each figure was a CD4+CD25+T cell subset). The proportions of CD4+CD25^high^ T-cells in CD4+T cells increased in groups A, B and C.

### Comparison of serum IL-2, IL-10 and IFN-γ

Compared with control group D, serum IL-10 levels in exendin-4 low-dose group A, medium-dose group B and high-dose group C increased (P\<0.05), while IL-2 and IFN-γ levels decreased (P\<0.05). The difference of serum IL-10, IL-2 and IFN-γ levels existing in IFN-γ was of statistical significance (P\<0.05) ([Table I](#tI-etm-0-0-3694){ref-type="table"}).

Discussion
==========

Previous findings have shown that the occurrence of type 1 diabetes involves phases such as cellular imbalance, inflammatory cell recruitment and inflammatory cell effect ([@b8-etm-0-0-3694]). The classical immunoregulation imbalance theory states that, the imbalance of Th1/Th2 cell subset and disorder of body immunologic functions are key factors inducing type 1 diabetes ([@b9-etm-0-0-3694],[@b10-etm-0-0-3694]). IL-2, IFN-γ and others are common Th1 cell factors that can upregulate pro-inflammatory factors, thus generating damage on pancreatic β cells. IL-10, IL-4 and others belong to Th2 cell factors, which can downregulate the activity of Th1 cells and have a preventative effect on type 1 diabetes ([@b11-etm-0-0-3694]). The present study has shown that compared with control group D, serum IL-10 levels in exendin-4 low-dose group A, medium-dose group B and high-dose group C increased (P\<0.05), while IL-2 and IFN-γ levels decreased (P\<0.05). The difference of the serum IL-10, IL-2 and IFN-γ levels existing among IFN-γ were of statistical significance (P\<0.05). Thus, it can be seen that exendin-4 intervention can reduce the expression of NOD mouse serum IL- 2 and IFN-γ, elevate the expression of serum IL-10 and exert a protective effect on pancreatic β cells.

T lymphocytes are closely related to diabetes pancreatitis. The inflammatory reaction induced by cell factors that are released by body CD4+T lymphocytes and cell toxic reaction mediated by body CD8+T lymphocytes are considered the main forms of cellular immunity induced by T lymphocytes ([@b12-etm-0-0-3694]--[@b14-etm-0-0-3694]). If CD4+T lymphocyte subsets gradually increase, then multiple types of cell factors can be released. While these cell factors, may enhance the inflammatory reaction of lymphocyte infiltration, form lethal effects on antigens and generate adverse effects, they also can facilitate cellular immunity and humoral immunity to a certain degree, and then promote effective removal of virus *in vivo*. Regulatory T-cells (CD4+CD25^high^ Foxp3+T reg) are a type of T-cell subset with immunomodulating functions that has been verified in recent years. It can maintain self-stabilization of an immune system while regulating the immune response ([@b15-etm-0-0-3694]--[@b17-etm-0-0-3694]). The present study has shown that CD4+CD25+T-cell proportions in pancreatic tissues of exendin-4 low-dose group A, medium-dose group B and high-dose group C were 5.31, 5.53 and 5.74%, respectively, all of which were higher than the CD4+CD25+T-cell proportion of 1.62% in control group D. CD4+CD25^high^ T-cells in groups A, B and C occupied an increasing proportion in CD4+T-cells. Studies have indicated that CD4+CD25^high^ T increased in NOD tumor infiltration lymphocytes under exendin-4 intervention, which may be associated with the fact that it exerted an immunosupressive effect by inhibiting the lethal effects of CD8+T cells through contact among cells ([@b18-etm-0-0-3694]).

Previous studies reported that, IL-10 can reduce the accumulated morbidity of diabetes, lower the inflammation degree of pancreas islets and relieve or prevent the occurrence and development of type 1 diabetes ([@b19-etm-0-0-3694],[@b20-etm-0-0-3694]). Notably diabetes is rarely diagnosed in an early phase. The lymphocyte infiltration degree may be serious once the patient is diagnosed with diabetes, and there are quite a few residual pancreatic β cells ([@b21-etm-0-0-3694]). The present findings have shown that pancreatitis of mice in control group D was mainly at grade 2 and 3, and under a light microscope, it was observed that pancreatic cell morphology was in disorder and the size and quantity of the pancreas was small. Pancreatitis in exendin-4 low-dose group A, medium-dose group B and high-dose group C was mainly at grade 0 and 1, and light microscopy showed that pancreatic cell morphology and lymphocyte infiltration improved, and the size of the pancreas was recovered. Additionally, a few brown granules with deep color were found within the pancreatic sample cells in control group D. IL-10 immunohistochemistry scores in low-dose group A, medium-dose group B and high-dose group C were (3.82±0.72), (4.34±0.86) and (4.81±0.94), respectively, all of which were higher than that in control group D (2.25±0.63). We conjectured that exendin-4 intervention elevates IL-10 levels in pancreatic tissues, downregulates bioactivity of Th1 cell factors through overexpression of IL-10, is regulated in the *in vivo* immune microenvironment and prevents the occurrence and development of diabetes.

In summary, NOD mouse body immune function is low, while the regulatory mechanism of its body immunity is in a state of disorder. Pancreatic tissue necrosis and inflammatory infiltration are serious. Exendin-4 intervention can exert certain regulatory effects on the IL-2, IFN-γ, IL-10 and T lymphocyte subset of NOD mice. By reducing the expression of serum IL- 2 and IFN-γ, it elevates IL-10 expression in serum and pancreatic tissues and increases the quantity of CD8+, CD4+ and CD25+ T cells in pancreatic tissues, thus eliminating inflammatory factors, boosting pancreatic tissue recovery and improving lymphocyte infiltration degree. Thus, the results of the current study, revealed the mechanism involved in exendin-4 on NOD mouse blood and the pancreatic tissue immune microenvironment.

The present study was funded by the Natural Science Foundation of Fujian province (grant no. 2016J01650).
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###### 

Comparison of serum IL-2, IL-10 and IFN-γ in the four groups.

  Group                 No.   IL-2 (pg/ml)                                                                                             IL-10 (pg/ml)                                                                                              IFN-γ (pg/ml)
  --------------------- ----- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Low-dose group A      10    61.12±9.48^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"}^                                                 195.67±20.15^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"}^                                                 321.36±28.26^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"}^
  Medium-dose group B   10    58.36±8.97^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"},[b](#tfn3-etm-0-0-3694){ref-type="table-fn"}^    213.92±21.84^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"},[b](#tfn3-etm-0-0-3694){ref-type="table-fn"}^    303.46±25.37^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"},[b](#tfn3-etm-0-0-3694){ref-type="table-fn"}^
  High-dose group C     10    53.15±8.26^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"}--[c](#tfn4-etm-0-0-3694){ref-type="table-fn"}^   238.72±23.34^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"}--[c](#tfn4-etm-0-0-3694){ref-type="table-fn"}^   285.48±22.65^[a](#tfn2-etm-0-0-3694){ref-type="table-fn"}--[c](#tfn4-etm-0-0-3694){ref-type="table-fn"}^
  Control group D       10    81.34±10.27                                                                                              162.66±18.37                                                                                               363.57±31.28

Compared with control group D

P\<0.05; compared with low-dose group A

P\<0.05; compared with medium-dose group B

P\<0.05.
